IQVIA

Bill Frohlich and David Dubow launched IMS Health in 1954, establishing what would become the primary source of physician prescribing data in the United States. That original venture carried a hidden stake from Arthur Sackler, linking its early history to the pharmaceutical giant Purdue Pharma. For decades, the firm dominated the market by collecting critical insights that shaped drug strategies across the industry.

The company went private under TPG Capital in 2010 before returning to the public market on April 4, 2014, trading as IMS on the NYSE. A major shift occurred in 2016 when IMS Health merged with Quintiles, a leading clinical research organization, to form QuintilesIMS. By January 2017, the entity officially rebranded as IQVIA to reflect an expanded focus on advanced analytics and technology beyond traditional data collection.

Headquartered originally in Danbury, Connecticut, the company moved its global headquarters to Durham, North Carolina, where it remains today. As the world's largest provider of biopharmaceutical development services and commercial outsourcing, IQVIA operates in over 100 countries. Recent financial reports highlight a stock price hitting a 52-week high of $260.32 in August 2026, marking a 38.4% return over the preceding year.

In March 2026, the company unveiled IQVIA.ai, a unified agentic AI platform powered by NVIDIA designed to improve efficiency and decision-making across the life sciences sector. This push into artificial intelligence continued into August 2026 when an IQVIA AI-enabled clinical decision support tool won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year. [edit]